Zymeworks Inc. (NASDAQ:ZYME – Get Free Report) has received an average recommendation of “Moderate Buy” from the twelve analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $41.00.
A number of research analysts recently commented on the company. JPMorgan Chase & Co. increased their price target on Zymeworks from $31.00 to $33.00 and gave the company an “overweight” rating in a report on Thursday, September 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zymeworks in a research note on Friday, July 17th. Deutsche Bank Aktiengesellschaft set a $32.00 price target on shares of Zymeworks in a research report on Wednesday, August 26th. Wells Fargo & Company lifted their price target on shares of Zymeworks from $37.00 to $40.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Truist Financial upped their price target on shares of Zymeworks from $31.00 to $32.00 and gave the company a “buy” rating in a report on Friday, August 7th.
Read Our Latest Research Report on Zymeworks
Institutional Investors Weigh In On Zymeworks
Zymeworks Price Performance
Shares of NASDAQ ZYME opened at $27.57 on Friday. The company has a 50-day simple moving average of $25.84 and a 200-day simple moving average of $25.40. The company has a market cap of $1.96 billion, a PE ratio of -13.65 and a beta of 1.19. Zymeworks has a 12 month low of $15.81 and a 12 month high of $31.34.
Zymeworks (NASDAQ:ZYME – Get Free Report) last released its earnings results on Friday, August 7th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.06). The business had revenue of $3.23 million for the quarter, compared to analysts’ expectations of $4.54 million. Zymeworks had a negative return on equity of 72.30% and a negative net margin of 405.31%.The business’s quarterly revenue was down 90.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.03 earnings per share. On average, analysts anticipate that Zymeworks will post 1.38 EPS for the current year.
About Zymeworks
Zymeworks Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company uses its proprietary Azymetric and EFECT antibody-engineering platforms to design multifunctional biotherapeutics, including bispecific antibodies and antibody-drug conjugates intended to address complex disease biology.
Zymeworks’ leading product is zanidatamab, a bispecific antibody targeting HER2. In the United States, zanidatamab is marketed as Ziiたhera for previously treated, unresectable or metastatic HER2-positive biliary tract cancer.
Featured Stories
- Five stocks we like better than Zymeworks
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.
